Newmont Corporation vs Nuwellis Inc — how do they compare? Newmont Corporation trades at $92.38 (market cap $95.23B), while Nuwellis Inc trades at $2.84 (market cap $1.09M). The key difference: Newmont Corporation is far larger — about 87367× Nuwellis Inc's market cap, and Newmont Corporation pays a 1.17% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NEM | NUWE | |
|---|---|---|
Market Cap | $95.23B | $1.09M |
Sector | Basic Materials | Technology |
52-Week High | $131.95 | $527.46 |
52-Week Low | $59.86 | $2.80 |
Enterprise Value | $91.98B | -$722.58K |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Trailing returns across standard periods
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →